Hyperphosphatemia
ICD-10 E83.3 · ICD-11 GB90.48

Hyperphosphatemia in Chronic Kidney Disease Stages 1–3 When Dietary Phosphate Restriction Has Not Achieved the Phosphorus Target

Patients with chronic kidney disease stages 1 to 3 and a serum phosphorus concentration above 4.5 mg/dL have hyperphosphatemia that warrants active management. When the first-line approach of dietary restriction has not brought serum phosphorus to the clinical goal, a structured next step is indicated.

Clinical Scenario

Chronic kidney disease stages 1 to 3; serum phosphorus concentration >4.5 mg/dL. Hyperphosphatemia is defined by a serum phosphorus concentration of >4.5 mg/dL (1.45 mmol/L).

Prior Treatment — Target Not Reached

Dietary restriction of phosphate and protein was the initial line of management. The goal was to achieve a serum phosphorus concentration of 2.7 to 4.6 mg/dL. This protocol applies when that target has not been met despite dietary measures.

Next-Step Approach (Partial)

When dietary measures have not controlled serum phosphorus in CKD stages 1 to 3, the protocol introduces an oral calcium-based phosphate-binding agent. The full selection, sequencing, and management details are in the complete protocol.

Treatment Target

Achieve a serum phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis.

Instant Access to Structured Evidence-Based Regimens

References

  1. Hyperphosphatemia is defined by a serum phosphorus concentration of >4.5 mg/dL (1.45 mmol/L).
  2. Hyperphosphatemia in CKD stages 1 to 3 can typically be controlled with dietary changes.
  3. These guidelines recommend that for high phosphorus uncontrolled by dietary measures, calcium-based phosphate binders are a reasonable choice for CKD stages 3 and 4.
  4. Phosphate binders such as aluminum-based antacids, magnesium-based antacids, calcium carbonate, calcium acetate, sevelamer, and lanthanum may be necessary for those patients whose phosphorus levels stay elevated despite dietary restrictions.
  5. In general, the goal is to achieve a phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis.
View source ↗